Product Description
GlaxoSmithKline was developing gsk-2585823, a Topical agent for Treatment of Acne Vulgaris. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01445301)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acne Vulgaris
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-111640 |
JapicCTI-111640 | N/A |
Completed |
Acne Vulgaris |
None |
|||
NCT01527123 |
NCT01527123 | P1 |
Completed |
Acne Vulgaris |
2012-06-01 |
2019-03-19 |
Treatments |
|
NCT01428466 |
JPN P1 | P1 |
Completed |
Acne Vulgaris |
2011-02-15 |
2019-03-19 |
||
NCT01445301 |
NCT01445301 | P3 |
Completed |
Acne Vulgaris |
2012-08-02 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|